NSC625987 | CAS#141992-47-4 | CDK4/CyclinD1 inhibitor

MedKoo Cat#: 527750 | Name: NSC625987

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NSC625987, also known as Cdk4 Inhibitor II, is a highly selective inhibitor of CDK4/CyclinD1.

Chemical Structure

NSC625987

CAS#141992-47-4

Theoretical Analysis

MedKoo Cat#: 527750

Name: NSC625987

CAS#: 141992-47-4

Chemical Formula: C15H13NO2S

Exact Mass: 271.0667

Molecular Weight: 271.33

Elemental Analysis: C, 66.40; H, 4.83; N, 5.16; O, 11.79; S, 11.82

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 350.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

NSC 625987; NSC-625987; NSC625987; Cdk4 Inhibitor II.

IUPAC/Chemical Name

1,4-Dimethoxy-10H-acridine-9-thione

InChi Key

KFAKESMKRPNZTM-UHFFFAOYSA-N

InChi Code

InChI=1S/C15H13NO2S/c1-17-11-7-8-12(18-2)14-13(11)15(19)9-5-3-4-6-10(9)16-14/h3-8H,1-2H3,(H,16,19)

SMILES Code

S=C1C2=C(C=CC=C2)NC3=C(OC)C=CC(OC)=C13

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

NSC 625987 is a specific and high-affinity CDK4 inhibitor with an IC50 of 0.2 μM for CDK4:cyclin D1.

In vitro activity:

One compound, 3-amino thioacridone (3-ATA; NSC 680434), whose growth-inhibitory activity correlated with the p16 status of the cell lines had an IC50 of 3.1 microM in a CDK4 kinase assay. ATP competition experiments demonstrated a noncompetitive mode of inhibition for 3-ATA (K(i) = 5.5 microM) and a linear mixed mode for benzothiadiazine (NSC 645787; K(i) = 0.73 microM). Reference: Clin Cancer Res. 1999 Dec;5(12):4279-86. https://pubmed.ncbi.nlm.nih.gov/10632371/

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMSO	100.0	368.55

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 271.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Diccianni MB, Yu J, Meppelink G, de Vries M, Shao L, Gebauer S, Shih H, Roberts W, Kilcoin NP, Pullen J, Carson DA, Yu AL. 3-amino thioacridone inhibits DNA synthesis and induce DNA damage in T-cell acute lymphoblastic leukemia (T-ALL) in a p16-dependent manner. J Exp Ther Oncol. 2004 Oct;4(3):223-37. PMID: 15724842. 2. Kubo A, Nakagawa K, Varma RK, Conrad NK, Cheng JQ, Lee WC, Testa JR, Johnson BE, Kaye FJ, Kelley MJ. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res. 1999 Dec;5(12):4279-86. PMID: 10632371.

In vitro protocol:

In vivo protocol:

TBD

1: Lang E, Zelenak C, Eberhard M, Bissinger R, Rotte A, Ghashghaeinia M, Lupescu A, Lang F, Qadri SM. Impact of cyclin-dependent kinase CDK4 inhibition on eryptosis. Cell Physiol Biochem. 2015;37(3):1178-86. doi: 10.1159/000430241. Epub 2015 Sep 29. PubMed PMID: 26418250.